You are here

Blood Screening Market Forecasts, 2019-2024 - Nucleic Acid Testing (NAT), Blood Banks, and North America Dominate their Segments, Respectively

DUBLIN, Dec. 17, 2019 /PRNewswire/ -- The "Blood Screening Market by Technology (Nucleic Acid Amplification, (Real Time PCR), ELISA (Chemiluminescence Immunoassay), Rapid Test, Western Blot), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecast to 2024" report has been added to's offering.

The blood screening market is projected to reach USD 3.3 billion by 2024 from USD 2.2 billion in 2019, at a CAGR of 8.7%.

This report provides a detailed picture of the global blood screening market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens are driving the overall growth of the blood screening market

Growth in this market is driven by the increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens. Technological advancements and developing economies are expected to present opportunities for growth for players in the blood screening market. However, the need to reduce blood screening prices is a major factor in challenging market growth.

Nucleic Acid Testing (NAT) segment accounted for the larger share of the blood screening market, by technology, in 2018

The blood screening market, by technology, has been segmented into nucleic acid testing (NAT), enzyme-linked immunosorbent assays (ELISA), rapid tests, western blot assays, and next-generation sequencing (NGS). The NAT segment dominates the blood screening market, by technology, primarily due to the increasing number of blood donations and the increasing adoption of NAT technology due to its higher sensitivity over other blood screening technologies. Based on type, the blood screening market for NAT is segmented into transcription-mediated amplification (TMA) and real-time PCR. Among these, the TMA segment accounts for the larger market share due to the higher sensitivity of this assay.

Blood banks to register the highest growth in the blood screening market during the forecast period

Based on end-users, the blood screening market is segmented into blood banks and hospitals. The blood bank segment accounted for the larger market share in 2018 and is projected to witness a higher growth rate during the forecast period. This can be attributed to the increasing demand for donated blood, a growing number of organ transplantation surgeries, rising awareness regarding the safety of blood, increasing the number of donations worldwide, and growth in government funding to charitable trusts.

North America will continue to dominate the blood screening market during the forecast period

Based on the region, the blood screening market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2018, North America accounted for the largest market share, followed by Europe. Factors such as the increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens, the presence of high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players in the region are driving the growth of the blood screening market in North America.

Key Topics Covered

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Blood Screening: Market Overview
4.2 Asia Pacific: Market Share, By End User & Country (2018)
4.3 Market, By Product & Service, 2019 Vs. 2024 (USD Million)
4.4 Geographical Snapshot of the Market

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers Increasing Demand for Donated Blood and Rising Number of Blood Donations Rising Prevalence of Infectious Diseases and Introduction of Newer Pathogens
5.2.2 Opportunities Technological Advancements Emerging Economies
5.2.3 Challenges Need for Reducing Blood Screening Prices

6 Blood Screening Market, By Product & Service
6.1 Introduction
6.2 Reagents & Kits
6.2.1 NAT Reagents & Kits High Sensitivity and Rising use of NAT are Boosting Demand for Related Reagents and Kits Enzymes & Polymerases Standards & Controls Probes & Primers Buffers, Nucleotides, & Solutions Labeling & Detection Reagents
6.2.2 Elisa Reagents & Kits Ease of use and Cost-Effectiveness of Elisa Reagents & Kits Will Drive Market Growth Immunosorbents Controls Conjugates Substrates Sample Diluents and Wash Solutions
6.2.3 Other Reagents Increasing use of Western Blot Tests and Rapid Tests Will Drive the Growth of This Market Segment
6.3 Instruments
6.3.1 Rental Purchase Convenience and Cost-Effectiveness of Renting Instruments has Resulted in Greater End-User Preference
6.3.2 Outright Purchase Availability of Government Support Will Increase the Outright Purchase of Instruments
6.4 Software & Services
6.4.1 Increasing Adoption of Instruments Will Drive the Demand for Related Software and Services

7 Blood Screening Market, By Technology
7.1 Introduction
7.2 Nucleic Acid Testing (NAT)
7.2.1 Transcription-Mediated Amplification Highest Sensitivity of These Assays to Support Market Growth
7.2.2 Real-Time Polymerase Chain Reaction (PCR) Real-Time PCR Procedures Provide More Accurate and Effective Results as Compared to Conventional PCR
7.3 Enzyme-Linked Immunosorbent Assays
7.3.1 Chemiluminescence Immunoassays Clia is Ultrasensitive, Automated, and a Good Alternative to Conventional Methodologies
7.3.2 Fluorescent Immunoassays Rising Demand for Safer and Stable Reagents and the Development of Novel Markers to Support the Growth of This Market Segment
7.3.3 Colorimetric Immunoassays CI Offers Low Sensitivity as It Uses Vulnerable/Limited Signal Amplification Strategies
7.4 Rapid Tests
7.4.1 Rising Awareness About Rapid Tests in Emerging Countries Have Increased the Adoption of These Tests
7.5 Western Blot Assays
7.5.1 Growing Prevalence of TTIS in Developing Countries has Resulted in the Increased Demand for Western Blot Assays
7.6 Next-Generation Sequencing
7.6.1 Ngs is an Emerging Technology in the Market

8 Blood Screening Market, By End User
8.1 Introduction
8.2 Blood Banks
8.2.1 Blood Banks Hold the Largest Share of the Market
8.3 Hospitals
8.3.1 Increasing Number of Surgical Procedures Will Drive the Growth of the Hospitals Segment

9 Blood Screening Market, By Region
9.1 Introduction
9.2 North America
9.2.1 US The US Dominates the Global Market
9.2.2 Canada High Incidence of Sexually Transmitted Diseases in the Country to Support Market Growth
9.3 Europe
9.3.1 Germany Germany is the Largest Market for Blood Screening Technologies in Europe
9.3.2 France Increasing Prevalence of HIV to Support Market Growth
9.3.3 UK Government Support to Prevent Transmission of HIV and Other Infections Will Drive Growth
9.3.4 Italy Italy is Witnessing an Increase in the Number of Blood Donors
9.3.5 Spain Increasing Adoption of NAT Technology Will Support Market Growth
9.3.6 RoE
9.4 Asia Pacific
9.4.1 China China has a High Prevalence of Infectious Diseases
9.4.2 Japan Japan has Witnesses an Increase in the Adoption of Advanced Blood Screening Technologies
9.4.3 India Increasing Number of Road Accidents Will Support Market Growth
9.4.4 Australia Rising Number of Blood Donations Will Propel Market Growth
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil Increasing Incidence of Cancer Will Support the Growth of This Market
9.5.2 Rest of Latin America
9.6 Middle East & Africa
9.6.1 Rising Prevalence of Infectious Diseases Will Drive Market Growth in the Region

10 Competitive Landscape
10.1 Overview
10.2 Market Share Analysis, 2018
10.2.1 Market Share Analysis for NAT Blood Screening, 2018
10.2.2 Market Share Analysis for Total Market, 2018
10.3 Competitive Scenario
10.3.1 Partnerships, Agreements, and Collaborations (2017-2019)
10.3.2 Product Launches (2017-2019)
10.3.3 Expansions (2017-2019)
10.3.4 Acquisitions (2017-2019)
10.4 Competitive Leadership Mapping (2019)
10.4.1 Vendor Inclusion Criteria
10.4.2 Visionary Leaders
10.4.3 Innovators
10.4.4 Dynamic Differentiators
10.4.5 Emerging Companies

11 Company Profiles
11.1 Grifols
11.2 F. Hoffmann-La Roche
11.3 Abbott Laboratories
11.4 bioMerieux
11.5 Bio-Rad Laboratories
11.6 Becton, Dickson & Company
11.7 Danaher Corporation
11.8 Ortho Clinical Diagnostics
11.9 Siemens Healthineers
11.10 Thermo Fisher Scientific
11.11 DiaSorin
11.12 GE Healthcare
11.13 Merck KGaA
11.14 Perkinelmer
11.15 Bio-Techne
11.16 GFE
11.17 Trinity Biotech
11.18 J. Mitra Diagnostics Pvt. Ltd.

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:

SOURCE Research and Markets